Shares of AIM ImmunoTech Inc. (NYSE American: AIM) rocketed higher Wednesday, closing at $1.02, up 31 cents or 43.66%, on extraordinarily heavy trading volume exceeding 183 million shares as investors reacted to a key patent milestone and ongoing clinical advancements in its lead drug Ampligen for pancreatic cancer.
The penny stock opened at $1.45, traded in a wide range from $0.9665 to $1.62 and finished with a market capitalization around $4.3 million. Pre-market trading Thursday showed further pressure, dipping to about $0.90, down roughly 12%, reflecting typical volatility after such explosive moves in low-float biotech names.
